Arcturus Therapeutics Holdings Inc. (ARCT) shareholders
Close on Nov 13, 2026Market cap $237.62MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Ann C. Donahue Joint filing with Federated Hermes, Inc. (11.63%), Voting Shares Irrevocable Trust (11.63%) and 2 more | 3,303,640 | 11.63% | 13G (passive) amendment | Dec 31, 2025 |
| Catherine D. Wood Joint filing with ARK Investment Management LLC (10.37%) | 2,947,556 | 10.37% | 13G (passive) amendment | Apr 30, 2026 |
| Dmitry Balyasny Joint filing with Balyasny Asset Management L.P. (8.04%), Bam Gp LLC (8.04%) and 2 more | 2,183,985 | 8.04% | 13G (passive) | Sep 30, 2025 |
| BlackRock, Inc. | 2,104,537 | 7.80% | 13G (passive) amendment | Mar 31, 2025 |
| Amova Asset Management Americas, Inc. | 1,947,835 | 7.20% | 13G (passive) amendment | Sep 30, 2025 |
| Nikko Asset Management Americas, Inc. | 1,926,084 | 7.10% | 13G (passive) amendment | Mar 31, 2025 |
| Nikko Asset Management Co., Ltd. Joint filing with Sumitomo Mitsui Trust Group, Inc. (7.10%) | 1,926,084 | 7.10% | 13G (passive) amendment | Mar 31, 2025 |
| Amova Asset Management Co., Ltd. Joint filing with Sumitomo Mitsui Trust Group, Inc. (5.90%) | 1,689,107 | 5.90% | 13G (passive) amendment | Sep 30, 2026 |
| Voting Shares Irrevocable Trust Joint filing with Federated Hermes, Inc. (5.90%), Thomas R. Donahue (5.90%) and 2 more | 1,678,069 | 5.90% | 13G (passive) amendment | Sep 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ARCT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Federated Hermes, Inc. | 3,303,640 | 11.62% | $22.20M | – | 0.03% |
| ARK Investment Management LLC | 2,901,635 | 10.21% | $19.50M | +132,117 | 0.13% |
| BlackRock, Inc. | 2,614,012 | 9.20% | $17.57M | +731 | 0.00% |
| Sumitomo Mitsui Trust Holdings, Inc. | 1,963,123 | 6.91% | $13.19M | −325,812 | 0.01% |
| Nikko Asset Management Americas, Inc. | 1,960,458 | 6.90% | $13.14M | −328,477 | 0.17% |
| Vanguard Capital Management LLC | 1,114,956 | 3.92% | $7.49M | +7,936 | 0.00% |
| Two Sigma Investments, LP | 1,091,137 | 3.84% | $7.33M | +9,353 | 0.01% |
| Vanguard Portfolio Management LLC | 951,575 | 3.35% | $6.39M | −26,347 | 0.00% |
| Geode Capital Management, LLC | 693,660 | 2.44% | $4.66M | +32,732 | 0.00% |
| Aqr Capital Management LLC | 675,014 | 2.37% | $4.54M | +513,736 | 0.00% |
| Jacobs Levy Equity Management, Inc | 647,511 | 2.28% | $4.35M | +448,783 | 0.02% |
| State Street Corp | 569,598 | 2.00% | $3.83M | +25,735 | 0.00% |
| UBS Group AG | 490,632 | 1.73% | $3.30M | +32,355 | 0.00% |
| D. E. Shaw & Co., Inc. | 392,358 | 1.38% | $2.64M | +140,324 | 0.00% |
| Empire Life Investments Inc. | 366,217 | 1.29% | $2.46M | −17,276 | 0.14% |
| Hennion & Walsh Asset Management, Inc. | 346,207 | 1.22% | $2.33M | +66,528 | 0.07% |
| Millennium Management LLC | 336,996 | 1.19% | $2.26M | −141,561 | 0.00% |
| Goldman Sachs Group Inc | 309,863 | 1.09% | $2.08M | +111,182 | 0.00% |
| Bnp Paribas Arbitrage, Snc | 261,789 | 0.92% | $1.76M | +66,929 | 0.00% |
| Charles Schwab Investment Management Inc | 231,628 | 0.81% | $1.56M | +15,128 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 135 | 25M | 87.9% | 20 / 56 | 40 / 8 | 3M | 2M |
| Q1 2026 | 124 | 24M | 85.5% | 28 / 47 | 36 / 23 | 5M | 3M |
| Q4 2025 | 120 | 24M | 83.6% | 28 / 35 | 38 / 42 | 5M | 7M |
| Q3 2025 | 136 | 26M | 91.7% | 22 / 50 | 39 / 28 | 3M | 3M |
| Q2 2025 | 143 | 26M | 91.1% | 26 / 50 | 39 / 26 | 2M | 3M |
| Q1 2025 | 144 | 27M | 93.6% | 22 / 46 | 49 / 24 | 2M | 2M |
| Q4 2024 | 147 | 27M | 93.8% | 15 / 55 | 47 / 31 | 3M | 3M |
| Q3 2024 | 164 | 27M | 93.3% | 24 / 57 | 49 / 30 | 6M | 3M |
| Q2 2024 | 171 | 27M | 93.4% | 35 / 45 | 65 / 40 | 3M | 5M |
| Q1 2024 | 179 | 29M | 100.0% | 33 / 55 | 62 / 18 | 5M | 2M |
| Q4 2023 | 165 | 26M | 92.6% | 36 / 53 | 54 / 14 | 3M | 2M |
| Q3 2023 | 145 | 25M | 88.4% | 22 / 51 | 52 / 20 | 3M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
146 funds held ARCT in Q2 2026, 51% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ARCT | Value | % of fund | As of |
|---|---|---|---|---|---|
| ARK Genomic Revolution ETF | 2,741,123 | 9.64% | $15.79M | 1.01% | Jul 31, 2026 |
| Federated Hermes Kaufmann Fund | 1,962,580 | 6.90% | $11.30M | 0.23% | Jul 31, 2026 |
| Federated Hermes Kaufmann Small Cap Fund | 1,186,700 | 4.18% | $6.84M | 0.24% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 797,154 | 2.80% | $5.36M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 712,395 | 2.51% | $4.79M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 293,104 | 1.03% | $1.97M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 292,439 | 1.03% | $1.68M | 0.00% | Jul 31, 2026 |
| Vanguard Explorer Fund | 285,663 | 1.01% | $1.65M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 254,094 | 0.89% | $1.71M | 0.01% | Jun 30, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 253,764 | 0.89% | $1.71M | 0.05% | Jun 30, 2026 |
| iShares Biotechnology ETF | 183,754 | 0.65% | $1.23M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 138,170 | 0.49% | $1.09M | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 136,565 | 0.48% | $1.08M | 0.01% | May 31, 2026 |
| BlackRock Advantage Small Cap Core Fund | 135,078 | 0.48% | $1.07M | 0.02% | May 29, 2026 |
| Schwab U.S. Small-Cap ETF | 131,117 | 0.46% | $1.04M | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Joseph E. Payne | President and CEO, Director | 1,480,097 | 5.21% | Dec 19, 2025 |
| Andy Sassine | Chief Financial Officer, Director | 221,764 | 0.78% | Aug 20, 2025 |
| Dennis Mulroy | Chief Financial Officer | – | – | May 7, 2026 |
| Pad Chivukula | Chief Scientific Officer & COO | 435,334 | 1.53% | Dec 19, 2025 |
| Lance Kurata | Chief Legal Officer | – | – | Dec 19, 2025 |
| Joseph Roberts | Controller | 2,201 | 0.01% | Dec 19, 2025 |
| Jing L. Marantz | Director | 3,131 | 0.01% | Jun 15, 2026 |
| Magda Marquet | Director | 28,073 | 0.10% | Jun 15, 2026 |
| Peter C. Farrell | Director | 98,696 | 0.35% | Jun 15, 2026 |
| Moncef Slaoui | Director | – | – | Jun 15, 2026 |
| Edward W. Holmes | Director | 3,131 | 0.01% | Jun 15, 2026 |
| John Markels | Director | 3,131 | 0.01% | Jun 15, 2026 |
| James F. Barlow | Director | 13,131 | 0.05% | Jun 15, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Andy Sassine Chief Financial Officer, Director | Aug 15, 2025 | Buy | +1,238 | $16.56 | $20.50K | 221,764 |
| Andy Sassine Chief Financial Officer, Director | Aug 15, 2025 | Buy | −1,238 | $16.56 | $20.50K | 221,764 |
| Pad Chivukula Chief Scientific Officer & COO | Oct 15, 2024 | Sale(10b5-1 plan) | −12,000 | $20.76 | $249.12K | 435,334 |
| Magda Marquet Director | Jun 14, 2024 | Option exercise | +3,131 | – | – | 3,131 |
| Edward W. Holmes Director | Jun 14, 2024 | Option exercise | +3,131 | – | – | 3,131 |
| John Markels Director | Jun 14, 2024 | Option exercise | +3,131 | – | – | 3,131 |
| James F. Barlow Director | Jun 14, 2024 | Option exercise | +3,131 | – | – | 13,131 |
| Peter C. Farrell Director | Jun 14, 2024 | Option exercise | +3,131 | – | – | 55,741 |
| Jing L. Marantz Director | Jun 14, 2024 | Option exercise | +3,131 | – | – | 3,131 |
| Andy Sassine Chief Financial Officer, Director | Jun 12, 2024 | Sale | −50,000 | $32.03 | $1.60M | 220,526 |
| Pad Chivukula Chief Scientific Officer & COO | Jun 5, 2024 | Sale(10b5-1 plan) | −114 | $45.00 | $5.13K | 447,334 |
| Pad Chivukula Chief Scientific Officer & COO | Jun 3, 2024 | Sale(10b5-1 plan) | −26,000 | $40.01 | $1.04M | 447,448 |
| Pad Chivukula Chief Scientific Officer & COO | Mar 25, 2024 | Sale(10b5-1 plan) | −17,435 | $35.02 | $610.57K | 473,448 |
| Pad Chivukula Chief Scientific Officer & COO | Mar 19, 2024 | Sale(10b5-1 plan) | −8,565 | $35.01 | $299.86K | 490,883 |
| Pad Chivukula Chief Scientific Officer & COO | Nov 1, 2023 | Sale(10b5-1 plan) | −5,000 | $18.72 | $93.60K | 499,448 |
| Pad Chivukula Chief Scientific Officer & COO | Oct 2, 2023 | Sale(10b5-1 plan) | −5,000 | $25.61 | $128.05K | 504,448 |
| Pad Chivukula Chief Scientific Officer & COO | Sep 1, 2023 | Sale(10b5-1 plan) | −5,000 | $31.45 | $157.25K | 509,448 |
| Andy Sassine Chief Financial Officer, Director | Aug 15, 2023 | Award | +1,223 | $17.37 | $21.24K | 270,526 |
| Pad Chivukula Chief Scientific Officer & COO | Aug 1, 2023 | Sale(10b5-1 plan) | −5,000 | $34.91 | $174.55K | 514,448 |
| Keith C. Kummerfeld See Remarks | Jul 14, 2023 | Option exercise | +1,437 | $4.99 | $7.17K | 6,887 |
| Keith C. Kummerfeld See Remarks | Jul 14, 2023 | Option exercise | +4,500 | $9.04 | $40.68K | 5,450 |
| Keith C. Kummerfeld See Remarks | Jul 14, 2023 | Option exercise | +1,031 | $14.12 | $14.56K | 7,918 |
| Keith C. Kummerfeld See Remarks | Jul 14, 2023 | Sale(10b5-1 plan) | −6,968 | $35.00 | $243.88K | 950 |
| Pad Chivukula Chief Scientific Officer & COO | Jul 14, 2023 | Sale(10b5-1 plan) | −25,000 | $35.01 | $875.25K | 519,448 |
| Pad Chivukula Chief Scientific Officer & COO | Jul 3, 2023 | Sale(10b5-1 plan) | −5,000 | $28.75 | $143.75K | 544,448 |
| Pad Chivukula Chief Scientific Officer & COO | Jun 1, 2023 | Sale(10b5-1 plan) | −5,000 | $27.16 | $135.80K | 549,448 |
| Pad Chivukula Chief Scientific Officer & COO | May 11, 2023 | Sale(10b5-1 plan) | −7,925 | $30.24 | $239.65K | 554,448 |
| Pad Chivukula Chief Scientific Officer & COO | May 10, 2023 | Sale(10b5-1 plan) | −17,075 | $30.00 | $512.25K | 562,373 |
| Pad Chivukula Chief Scientific Officer & COO | May 1, 2023 | Sale(10b5-1 plan) | −5,000 | $25.93 | $129.65K | 579,448 |
| Keith C. Kummerfeld See Remarks | Apr 18, 2023 | Option exercise | +1,031 | $14.12 | $14.56K | 1,981 |
| Keith C. Kummerfeld See Remarks | Apr 18, 2023 | Sale(10b5-1 plan) | −6,968 | $28.18 | $196.36K | 950 |
| Keith C. Kummerfeld See Remarks | Apr 18, 2023 | Option exercise | +1,437 | $4.99 | $7.17K | 7,918 |
| Keith C. Kummerfeld See Remarks | Apr 18, 2023 | Option exercise | +4,500 | $9.04 | $40.68K | 6,481 |
| Pad Chivukula Chief Scientific Officer & COO | Apr 3, 2023 | Sale(10b5-1 plan) | −5,000 | $25.38 | $126.90K | 584,448 |
| Pad Chivukula Chief Scientific Officer & COO | Mar 6, 2023 | Sale(10b5-1 plan) | −5,000 | $16.07 | $80.35K | 589,448 |
| Magda Marquet Director | Dec 15, 2022 | Buy | +2,222 | $18.00 | $40.00K | 24,942 |
| Joseph E. Payne President and CEO, Director | Nov 23, 2022 | Buy | +5,000 | $16.51 | $82.55K | 1,480,097 |
| Andy Sassine Chief Financial Officer, Director | Aug 15, 2022 | Award | +1,068 | $18.42 | $19.67K | 269,303 |
| Pad Chivukula Chief Scientific Officer & COO | Jan 4, 2022 | Sale(10b5-1 plan) | −8,100 | $40.00 | $324.00K | 594,448 |
| Pad Chivukula Chief Scientific Officer & COO | Dec 16, 2021 | Sale(10b5-1 plan) | −3,633 | $40.00 | $145.32K | 602,548 |
| Pad Chivukula Chief Scientific Officer & COO | Dec 8, 2021 | Sale(10b5-1 plan) | −6,367 | $40.00 | $254.68K | 606,181 |
| Pad Chivukula Chief Scientific Officer & COO | Nov 1, 2021 | Sale(10b5-1 plan) | −10,000 | $44.41 | $444.10K | 612,548 |
| Pad Chivukula Chief Scientific Officer & COO | Oct 1, 2021 | Sale(10b5-1 plan) | −10,000 | $44.36 | $443.60K | 622,548 |
| Pad Chivukula Chief Scientific Officer & COO | Sep 1, 2021 | Sale(10b5-1 plan) | −10,000 | $55.86 | $558.60K | 632,548 |
| Pharmaceutical Inc. Ultragenyx Director | Aug 11, 2021 | Sale | −75,000 | $45.83 | $3.44M | 1,400,000 |
| Pharmaceutical Inc. Ultragenyx Director | Aug 10, 2021 | Sale | −725,000 | $55.44 | $40.19M | 1,475,000 |
| Pad Chivukula Chief Scientific Officer & COO | Aug 3, 2021 | Sale(10b5-1 plan) | −10,000 | $40.07 | $400.70K | 642,548 |
| Pad Chivukula Chief Scientific Officer & COO | Apr 1, 2021 | Sale(10b5-1 plan) | −10,000 | $42.95 | $429.50K | 652,548 |
| Pad Chivukula Chief Scientific Officer & COO | Mar 1, 2021 | Sale(10b5-1 plan) | −10,000 | $54.23 | $542.30K | 662,548 |
| Pad Chivukula Chief Scientific Officer & COO | Feb 1, 2021 | Sale(10b5-1 plan) | −10,000 | $75.31 | $753.10K | 672,548 |
| Pad Chivukula Chief Scientific Officer & COO | Jan 4, 2021 | Sale(10b5-1 plan) | −10,000 | $46.40 | $464.00K | 682,548 |
| Pharmaceutical Inc. Ultragenyx Director, 10% owner | Dec 9, 2020 | Sale | −357,745 | $94.97 | $33.98M | 2,200,000 |
| Pharmaceutical Inc. Ultragenyx Director, 10% owner | Dec 8, 2020 | Sale | −442,255 | $105.54 | $46.68M | 2,557,745 |
| Pad Chivukula Chief Scientific Officer & COO | Dec 1, 2020 | Sale(10b5-1 plan) | −10,000 | $96.19 | $961.90K | 692,548 |
| Pad Chivukula Chief Scientific Officer & COO | Nov 2, 2020 | Sale(10b5-1 plan) | −10,000 | $55.28 | $552.80K | 702,548 |
| Pad Chivukula Chief Scientific Officer & COO | Oct 1, 2020 | Sale(10b5-1 plan) | −10,000 | $42.83 | $428.30K | 712,548 |
| Pad Chivukula Chief Scientific Officer & COO | Sep 3, 2020 | Sale(10b5-1 plan) | −10,000 | $45.16 | $451.60K | 722,548 |
| Keith C. Kummerfeld See Remarks | Jun 12, 2020 | Buy | +450 | $33.33 | $15.00K | 950 |
| Joseph E. Payne President and CEO, Director | Jun 10, 2020 | Buy | +1,000 | $31.69 | $31.69K | 1,475,097 |
| Andy Sassine Chief Financial Officer, Director | Jun 10, 2020 | Buy | +5,000 | $29.74 | $148.70K | 273,245 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Arcturus Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 30,622 shares on Sep 4, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Pad Chivukula Officer | Oct 15, 2024 | 12,000 | $249.12K | Oct 15, 2024 | FOUNDERS SHARES |
| Keith C. Kummerfeld Officer | Jun 18, 2024 | 2,000 | $64.00K | Jun 10, 2024 | STOCK OPTION EXERCISE |
| Andy Sassine Director | Jun 12, 2024 | 50,000 | $1.60M | Jun 12, 2024 | Market Purchase |
| Pad Chivukula Officer | Jun 5, 2024 | 37,000 | $1.67M | Jun 5, 2024 | Founders Shares |
| Pad Chivukula Officer | Jun 3, 2024 | 26,000 | $1.04M | Jun 3, 2024 | Founders Shares |
| Pad Chivukula Officer | Mar 19, 2024 | 26,000 | $910.00K | Mar 19, 2024 | Founders Shares |
| Pad Chivukula Officer | Oct 2, 2023 | 15,000 | $390.00K | Oct 2, 2023 | Founders Shares |
| Pad Chivukula Officer | Sep 1, 2023 | 5,000 | $155.00K | Sep 1, 2023 | FOUNDERS SHARES |
| Pad Chivukula Officer | Aug 1, 2023 | 5,000 | $175.00K | Aug 1, 2023 | Founders Shares |
| Pad Chivukula Officer | Jul 14, 2023 | 25,000 | $875.34K | Jul 14, 2023 | Founders Shares |
| Keith C. Kummerfeld Officer | Jul 14, 2023 | 6,968 | $243.88K | Jul 14, 2023 | Stock Option Exercise |
| Pad Chivukula Officer | May 11, 2023 | 7,925 | $239.68K | May 11, 2023 | Founders Shares |
| Pad Chivukula Officer | May 10, 2023 | 17,075 | $512.29K | May 10, 2023 | Founders Shares |
| Keith C. Kummerfeld Officer | Apr 17, 2023 | 6,968 | $196.34K | Apr 17, 2023 | STOCK OPTIONS |
See a number that looks wrong?